Dab­bling in CD47, Pfiz­er in­fus­es $25M in­to a biotech play­er tout­ing pos­i­tive monother­a­py da­ta

5 years ago
Deals
R&D

An­a­lysts as­sess fall­out af­ter As­traZeneca halts PhI­II Covid-19 vac­cine dos­ing to probe a pos­si­ble se­ri­ous ad­verse ...

5 years ago
R&D
Coronavirus

Phar­ma's bat­tered rep gets a mod­est facelift in the lat­est in­dus­try rat­ings from Gallup — but it's still look­ing ...

5 years ago
Bioregnum
Pharma

News brief­ing: Ex­elix­is rolls the dice with 2 ADC deals tied to $35M cash up­fronts; A rare an­tibi­ot­ic win for ...

5 years ago
News Briefing

Cell­tri­on to be­gin mass pro­duc­ing an­ti­body treat­ment be­fore get­ting ap­proval

5 years ago
R&D
Coronavirus

Up­start sets off on a clin­i­cal jour­ney, look­ing to make a name for its 2nd-gen CB1 block­ers

5 years ago
Financing

Ahead of merg­er with Pfiz­er's gener­ic unit, My­lan makes $757M+ pur­chase for Eu­ro­pean throm­bo­sis port­fo­lio

5 years ago
Deals

Mer­ck beat Bel­lus, but their full cough da­ta aren't earn­ing much en­thu­si­asm

5 years ago
R&D

Af­ter care­ful­ly build­ing up ex­pec­ta­tions, a small-cap biotech’s big plans come crash­ing down in PhI­II cat­a­stro­phe

5 years ago
R&D

Gri­fols makes a $146M bet on a Stan­ford play in a con­tro­ver­sial an­ti-ag­ing field

5 years ago
Deals
R&D

Roche nabs an FDA OK for Gavre­to, trig­ger­ing a heavy­weight bout with ri­vals at Eli Lil­ly

5 years ago
R&D
Pharma

Covid-19 roundup: Af­ter bat­ting back at vac­cine sup­pli­er, In­ovio lines up a gi­ant in its cor­ner; Ox­ford spin­out ...

5 years ago
Coronavirus

CEOs join reg­u­la­tors and top sci­en­tists vow­ing to hold the line on Covid-19 vac­cine. But will that get in the way of ...

5 years ago
Bioregnum
Coronavirus

Roche to read out even more da­ta on megablock­buster Ocre­vus in MS

5 years ago
R&D

Covid-19 roundup: Cure­Vac ex­pands cache to $1.3B as coro­n­avirus race heats up; Russ­ian sci­en­tists pub­lish ear­ly da­ta ...

5 years ago
Coronavirus

Ver­tex and Covid-19 spell the end for Savara's CF pro­gram

5 years ago
R&D

News brief­ing: Kite looks to ex­pand Yescar­ta fran­chise with new in­di­ca­tions; Tiny Lixte looks to up­list on Nas­daq

5 years ago
News Briefing

Close­ly-watched in­ter­na­tion­al CRISPR ethics pan­el leaves door ajar for germline edit­ing — one day

5 years ago
Cell/Gene Tx

Scott Ed­mond­son leaves As­traZeneca, starts new chap­ter at Nim­bus; With IPO filed, Taysha pulls to­geth­er an ...

5 years ago
Peer Review

Chi­na biotech In­xMed bags $19M Se­ries A+ to de­vel­op PhI FAK in­hibitor

5 years ago
Financing
R&D

Sam­sung con­struct­ing new $2B 'Su­per Plan­t' rough­ly the size of Amer­i­ca's largest malls

5 years ago
Outsourcing
Pharma

Ab­b­Vie jumps in­to CD47 game, en­gi­neers $3B deal with am­bi­tious Chi­nese play­er

5 years ago
Deals
China

Mon­cef Slaoui calls late Oc­to­ber vac­cine roll­out 'ex­treme­ly un­like­ly,' vows again to re­sign un­der un­due po­lit­i­cal ...

5 years ago
Coronavirus

Re­searchers at City of Hope com­bine on­colyt­ic virus with a CAR-T to erad­i­cate sol­id tu­mors in mice

5 years ago
Discovery
Cell/Gene Tx
First page Previous page 804805806807808809810 Next page Last page
A service from the Financial Times